var data={"title":"Etoposide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Etoposide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6169?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">see &quot;Etoposide: Drug information&quot;</a> and <a href=\"topic.htm?path=etoposide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Etoposide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708769\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Administer etoposide under the supervision of a qualified health care provider who is experienced in the use of cancer chemotherapeutic agents. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Severe myelosuppression, with resulting infection or bleeding, may occur.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169278\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Toposar</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14225985\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Etoposide Injection;</li>\n      <li>Etoposide Injection USP;</li>\n      <li>Vepesid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047333\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Mitotic Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Topoisomerase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047325\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">see &quot;Etoposide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dose, frequency, number of doses, and start date may vary by protocol and treatment phase; refer to individual protocols. Pediatric dosing units (eg, mg/kg, mg/m<sup>2</sup>) and routes (eg, IV, continuous IV infusion, intraventricular) are variable depending upon protocol/regimen; use extra precaution. Etoposide is associated with a low emetic risk (Dupuis 2011); antiemetics are recommended to prevent nausea and vomiting (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphocytic leukemia (ALL), relapsed or refractory:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Hijiya 2011:</i> Induction and Consolidation: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 hours for 5 consecutive days in Induction (in combination with cyclophosphamide and clofarabine) and 4 consecutive days in Consolidation (in combination with cyclophosphamide and clofarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Parker 2010</i>: ALL R3 Protocol: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Phase 2 Consolidation: IV: 100 mg/m<sup>2</sup> once daily on days 15 to 19 (in combination with other chemotherapeutic agents)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Phase 5 before continuation: IV: 150 mg/m<sup>2</sup> once daily on days 42, 49, 99, and 106 (in combination with other chemotherapeutic agents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute lymphoblastic leukemia (ALL) of infancy:</b> Limited data available (Dreyer 2010; Dreyer 2015): Infant &lt;1 year at diagnosis: 100 mg/m<sup>2</sup> over 2 hours once daily for 5 consecutive days; specific regimen days and combination chemotherapeutic agents variable dependent on protocol phase, refer to specific protocols</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML):</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gamis 2014:</i>\n      <b> Note:</b> Some aspects of protocol dosing presented in previous reports (Cooper 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Remission Induction: ADE (10 + 3 + 5) and ADE (8 + 3 + 5) regimens:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA &lt;0.6 m<sup>2</sup>: IV: 3.3 mg/<b>kg</b> once daily for 5 days (in combination with cytarabine and daunorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA &ge;0.6 m<sup>2</sup>: IV: 100 mg/m<sup>2 </sup>once daily for 5 days (in combination with cytarabine and daunorubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intensification I: AE regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA &lt;0.6 m<sup>2</sup>: IV: 5 mg/<b>kg</b> over 1 hour daily for 5 days (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA &ge;0.6 m<sup>2</sup>: IV: 150 mg/m<sup>2</sup> over 1 hour daily for 5 days (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gibson 2011:</i> Infants, Children, and Adolescents &lt;17 years: <b>Note:</b> For infants, the full dose was reduced by 25%:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction Course 1 (ADE 10 + 3 + 5, MAE 3 + 10 + 5 regimens):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 75 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;17 years: IV: 100 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction Course 2 (ADE 8 + 3 + 5, MAE 3 + 8 + 5 regimens):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 75 mg/m<sup>2</sup> once daily for 5 days (in combination cytarabine and daunorubicin or mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;17 years: IV: 100 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine and daunorubicin or mitoxantrone)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consolidation MACE or LAME 89/91 (Perel 2002):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: 75 mg/m<sup>2 </sup>over 1 hour once daily for 5 days (in combination with amsacrine and cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;17 years: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 5 days (in combination with cytarabine and daunorubicin or amsacrine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salvage treatment for refractory/recurrent disease<b>: </b>MEC regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV: Children &ge;5 years and Adolescents: IV: 80 mg/m<sup>2</sup> over 1 hour once daily for 6 days (in combination with cytarabine and mitoxantrone) (Amadori 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Adolescents &ge;15 years: IV: 200 mg/m<sup>2</sup>/<b>day</b> as a continuous infusion for 3 days (Day 8 to 10) (in combination with mitoxantrone and cytarabine) as a single course; may administer a second course if needed (Archimbaud 1991; Archimbaud 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS tumors, malignant (medulloblastoma, PNET, ependymoma, brainstem glioma):</b> Limited data available; multiple regimens reported:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Chi 2004; Fangusaro 2008: </i>Head Start II regimen: Infants and Children &lt;10 years:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: IV: 4 mg/<b>kg</b> once daily for 2 days on Day 2 and 3 of a 21-day cycle (cycle starts on Day 0) for 4 to 5 cycles (in combination with cisplatin, vincristine, cyclophosphamide/mesna and high-dose methotrexate/leucovorin)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consolidation with autologous peripheral blood stem cell rescue: IV: 250 mg/m<sup>2</sup> for 3 doses on Day -5 to -3 (in combination with carboplatin and thiotepa)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Duffner 1993</i>: Infants and Children &lt;3 years: IV: 6.5 mg/<b>kg </b>once daily administered on days 3 and 4 (in combination with cisplatin as Cycle B regimen) for a 28-day cycle alternating with Cycle A regimen (cyclophosphamide and vincristine); therapy initiated 2 to 4 weeks after tumor resection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Kovnar 1990:</i> Children &ge;6 years and Adolescents: IV: 150 mg/m<sup>2</sup>/dose once daily on days 3 and 4 (in combination with cisplatin) every 3 weeks for 4 cycles prior to radiation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Taylor 2003</i>: Children &ge;3 years and Adolescents: IV: 100 mg/m<sup>2</sup>/dose once daily on days 1, 2, and 3 (in combination with vincristine and carboplatin or cyclophosphamide) every 3 weeks for 4 cycles prior to radiation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS Nongerminomatous Germ Cell Tumor (NGGCT):</b> Limited data available (Goldman 2015): Children &ge;3 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction Cycles 1, 3, and 5: IV: 90 mg/m<sup>2</sup> once daily for 3 days on days 1 to 3 in combination with carboplatin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction Cycles 2, 4, and 6: IV: 90 mg/m<sup>2</sup> once daily for 5 days on days 1 to 5 in combination with ifosfamide</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>CNS tumors; relapsed, metastatic: </b>Limited data available (Fleischhack 2001; Pajtler 2016; Peyrl 2014): Intraventricular (using preservative-free formulation): Administer via an Ommaya-Rickham reservoir once daily for 5 consecutive days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: 0.25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Retinoblastoma, extraocular: </b>Limited data available (Chantada 2003): Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patient weight &lt;10 kg: IV: 3.3 mg/<b>kg</b> once daily on Days 1, 2, and 3 of a 21-day treatment cycle (in combination with carboplatin) alternating cycles with idarubicin and vincristine for a total of 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patient weight &ge;10 kg: IV: 100 mg/m<sup>2</sup> once daily on Days 1, 2, and 3 of a 21-day treatment cycle (in combination with carboplatin) alternating cycles with idarubicin and vincristine for a total of 8 cycles</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hematopoietic stem cell transplantation (HSCT), conditioning regimen:</b> Limited data available: Children &ge;1 year and Adolescents: IV: 30 <b>or</b> 60 mg/kg administered over 4 to 8 hours as a single dose 3 or 4 days prior to transplantation (Biagi 2000; Duerst 2000; Horning 1994; Snyder 1993; Zander 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ALL conditioning regimen: IV: Infants &ge;6 months, Children, and Adolescents: IV: 20 mg/<b>kg</b> once daily on days -4 to -2 (in combination with busulfan and fludarabine) (Lee 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Medulloblastoma conditioning regimen: Children &ge;7 years and Adolescents: IV: 250 mg/m<sup>2</sup> on days -5, -4, and -3 in combination with thiotepa and high-dose carboplatin (Dunkel 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma:</b> Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">High risk: BEACOPP regimen: Children and Adolescents: IV: 200 mg/m<sup>2</sup> on days 0, 1, and 2 of a 21-day treatment cycle for 4 cycles in combination with bleomycin, cyclophosphamide, doxorubicin, vincristine, prednisone, and procarbazine (Kelly 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermediate or high risk: ABVE-PC regimen: Children and Adolescents: IV: 125 mg/m<sup>2</sup> over 1 hour once daily for 3 days of a 21-day cycle for 2 to 4 cycles (in combination with doxorubicin, vincristine, cyclophosphamide, prednisone, and bleomycin) (Dharmarajan 2015; Friedman 2014; Schwartz 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuroblastoma, high-risk:</b> Limited data available: Children &ge;1 year and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: IV: 100 to 200 mg/m<sup>2</sup>/dose infused over 1 to 2 hours once daily for 3 to 5 consecutive days (in combination with other chemotherapy agents) (Kaneko 2002; Kushner 2004; Simon 2007; Simon 2007a); other reported regimens include 100 mg/m<sup>2</sup>/dose on day 2 and 5 (in combination with cisplatin, doxorubicin, and cyclophosphamide) every 28 days for 5 cycles (Matthay 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Myeloablative therapy with stem cell rescue:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 100 to 200 mg/m<sup>2</sup>/day for 4 to 5 days beginning 8 to 9 days prior to transplantation was used in 301 patients (Kaneko 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: 640 mg/m<sup>2</sup> infused over 96 hours beginning 8 days prior to transplant (Matthany 1999; Park 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salvage therapy: HD-ICE regimen: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 5 days in combination with ifosfamide and carboplatin with or without autologous peripheral blood stem cell support (depending on hematologic reserve)<i> (</i>Kushner 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ewing sarcoma: </b>Limited data available; multiple regimens reported:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HD-IE regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 5 days on days 1 to 5 of a 21-day cycle in combination with ifosfamide; frequency of cycles, and alternating chemotherapy combinations vary based on protocol (cyclophosphamide, vincristine, doxorubicin) (Grier 2003; Kushner 1995; Miser 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">VAC/IE Regimen: Children and Adolescents: IV: 150 mg/m<sup>2</sup> once daily for 3 doses on days 1 to 3 in combination with ifosfamide every 3 weeks alternating with VAC (vincristine, doxorubicin, cyclophosphamide) (Navid 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Relapsed, refractory: ICE regimen: IV: 100 mg/m<sup>2</sup> for 5 days every 3 to 4 weeks for up to 12 cycles in combination with carboplatin, ifosfamide, and mesna; or may follow with 2 courses of CAV (cyclophosphamide, doxorubicin, and vincristine) (Milano 2006; Van Winkle 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Malignant solid tumors, relapsed or metastatic disease:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IE regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 1 hour once daily for 3 to 5 days every 3 weeks in combination with ifosfamide (Kung 1993; Marina 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ICE regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup>/day for 5 days on days 0 to 4 every 3 weeks for up to 12 cycles in combination with carboplatin, ifosfamide, and mesna (Van Winkle 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Wilms tumor:</b> Limited data available (Abu-Ghosh 2002; Daw 2009): ICE Regimen: Children and Adolescents: IV: 100 mg/m<sup>2</sup> once daily for 3 to 5 doses (in combination with ifosfamide and carboplatin); repeat cycle every 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative (excludes HSCT dosing); manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Small cell lung cancer (in combination with other chemotherapy agents):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 35 mg/m<sup>2</sup>/day for 4 days, up to 50 mg/m<sup>2</sup>/day for 5 days every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Due to poor bioavailability, oral doses should be twice the IV dose (and rounded to the nearest 50 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Testicular cancer (in combination with other chemotherapy agents):</b> IV: 50 to 100 mg/m<sup>2</sup>/day on days 1 to 5 <b>or</b> 100 mg/m<sup>2</sup>/day on days 1, 3, and 5 repeated every 3 to 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: Dosage adjustments are not provided in the manufacturer&rsquo;s labeling; however, the following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR 10 to 50 mL/minute/1.73m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">GFR &lt;10 mL/minute/1.73m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis/peritoneal dialysis (PD) (after dialysis on dialysis days): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose and reduce for hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute: No adjustment required.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 15 to 50 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;15 mL minute: Data not available; consider further dose reductions</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">The following guidelines have been used by some clinicians:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &gt;50 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 10 to 50 mL/minute: Administer 75% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &lt;10 mL/minute: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Hemodialysis: Administer 50% of dose; supplemental posthemodialysis dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Peritoneal dialysis: Administer 50% of dose; supplemental dose is not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Janus 2010: Hemodialysis: Reduce dose by 50%; not removed by hemodialysis so may be administered before or after dialysis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 46 to 60 mL/minute: Administer 85% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl 31 to 45 mL/minute: Administer 80% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CrCl &le;30 mL/minute: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Floyd 2006): Bilirubin 1.5 to 3 mg/dL or AST &gt;3 times ULN: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, the following adjustments have been recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Donelli 1998: Liver dysfunction may reduce the metabolism and increase the toxicity of etoposide. Normal doses of IV etoposide should be given to patients with liver dysfunction (dose reductions may result in subtherapeutic concentrations); however, use caution with concomitant liver dysfunction (severe) and renal dysfunction as the decreased metabolic clearance cannot be compensated by increased renal clearance.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Floyd 2006: Bilirubin 1.5 to 3 mg/dL or AST &gt;3 times ULN: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">King 2001; Koren 1992: Bilirubin 1.5 to 3 mg/dL or AST &gt;180 units/L: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for toxicity: </b>The presented dosing adjustments are based on experience in adult patients; specific recommendations for pediatric patients are limited. Refer to specific protocol for management in pediatric patients if available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infusion (hypersensitivity) reactions: Interrupt infusion</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup> or platelets &lt;50,000/mm<sup>3</sup>: Withhold treatment until recovery</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe adverse reactions (nonhematologic): Reduce dose or discontinue treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169256\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Toposar: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL); 1 g/50 mL (50 mL) [contains alcohol, usp, polyethylene glycol 300, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (5 mL); 500 mg/25 mL (25 mL); 1 g/50 mL (50 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169241\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047337\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: In adults, doses &le;200 mg/day should be given as a single daily dose; doses &gt;200 mg should be given in 2 divided doses. If necessary, the injection may be used for oral administration either as an extemporaneous preparation. or by mixing dose with orange juice, apple juice, or lemonade (<b>NOT</b> grapefruit juice) at a final concentration not to exceed 0.4 mg/mL (to improve palatability) (Lam 2011; McLeod 1992).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: For IV infusion only; do not administer by rapid IV injection or by intrathecal, intraperitoneal, or intrapleural routes due to possible severe toxicity. Administer by continuous IV infusion or IV intermittent infusion via an in-line 0.22 micron filter over at least 60 minutes at a rate not to exceed 100 mg/m<sup>2</sup>/hour (or 3.3 mg/<b>kg</b>/hour). HSCT conditioning regimens have infused etoposide through a central venous catheter over 4 to 8 hours (Biagi 2000; Duerst 2000; Horning 1994; Snyder 1993; Zander 1997). Higher than recommended concentrations of etoposide infusions may crack hard plastic in chemo venting pins and infusion lines; inspect infusion solution for particulate matter and plastic devices for cracks and leaks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intraventricular: In pediatric patients, doses were injected over 2 minutes (Fleischhack 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132492\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration. For IV preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs). Double gloving, a gown, and (if dosage form allows) CSTDs are required during IV administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169272\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsules: Store oral capsules at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Dispense in a light-resistant container.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Injection: Store intact vials of injection at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F; do not freeze. According to the manufacturer&rsquo;s labeling, stability for solutions diluted for infusion in D<sub>5</sub>W or NS (in glass or plastic containers) varies based on concentration; 0.2 mg/mL solutions are  stable for 96 hours at room temperature and 0.4 mg/mL solutions are stable for 24 hours at room temperature (precipitation may occur at concentrations above 0.4 mg/mL).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Etoposide injection contains polysorbate 80 which may cause leaching of diethylhexyl phthalate (DEHP), a plasticizer contained in polyvinyl chloride (PVC) bags and tubing. Higher concentrations and longer storage time after preparation in PVC bags may increase DEHP leaching. Preparation in glass or polyolefin containers will minimize patient exposure to DEHP. When undiluted etoposide injection is stored in acrylic or ABS (acrylonitrile, butadiene and styrene) plastic containers, the containers may crack and leak. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047336\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of refractory testicular tumors (Parenteral: FDA approved in adults) and small cell lung cancer (Oral and parenteral: FDA approved in adults); has also been used for treatment of lymphoma, Hodgkin disease, leukemias (ALL, AML), neuroblastoma; Ewing sarcoma, retinoblastoma, Wilms tumor, and CNS tumors; and conditioning regimen with hematopoietic stem cell transplantation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169342\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Etoposide may be confused with teniposide</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Etoposide may be confused with etoposide phosphate (a prodrug of etoposide which is rapidly converted in the plasma to etoposide)</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">VePesid may be confused with Versed</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169338\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following may occur with higher doses used in stem cell transplantation: Alopecia, ethanol intoxication, hepatitis, hypotension (infusion-related), metabolic acidosis, mucositis, nausea and vomiting (severe), secondary malignancy, skin lesions (resembling Stevens-Johnson syndrome).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension (due to rapid infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Peripheral neuropathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea and vomiting, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia (nadir: 7 to 14 days; recovery: by day 20), thrombocytopenia (nadir: 9 to 16 days; recovery: by day 20)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction (including bronchospasm, chills, dyspnea, fever, tachycardia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Amenorrhea, apnea (hypersensitivity-associated), back pain, constipation, cortical blindness (transient), cough, cyanosis, diaphoresis, drowsiness, dysphagia, erythema, esophagitis, extravasation (induration/necrosis), facial swelling, fatigue, fever, hyperpigmentation, hypersensitivity reaction, interstitial pneumonitis, ischemic heart disease, laryngospasm, maculopapular rash, malaise, metabolic acidosis, mucositis, myocardial infarction, optic neuritis, ovarian failure, pruritic erythematous rash, pruritus, pulmonary fibrosis, radiation-recall phenomenon (dermatitis), reversible posterior leukoencephalopathy syndrome (RPLS), seizure, skin rash, Stevens-Johnson syndrome, tongue edema, toxic epidermal necrolysis, toxic megacolon, urticaria, vasospasm, weakness</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169262\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to etoposide or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Severe leukopenia or thrombocytopenia; severe hepatic impairment; severe renal impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169245\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe dose-limiting and dose-related myelosuppression with resulting infection or bleeding may occur.</b> Treatment should be withheld for platelets &lt;50,000/mm<sup>3</sup> or absolute neutrophil count (ANC) &lt;500/mm<sup>3</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Oral etoposide is associated with a low (adults) or moderate (children) emetic potential; antiemetics may be recommended to prevent nausea and vomiting (Dupuis 2011; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reaction: May cause anaphylactic-like reactions manifested by chills, fever, tachycardia, bronchospasm, dyspnea, and hypotension. In addition, facial/tongue swelling, coughing, chest tightness, cyanosis, laryngospasm, diaphoresis, hypertension, back pain, loss of consciousness, and flushing have also been reported less commonly. Incidence is primarily associated with intravenous administration (up to 2%) compared to oral administration (&lt;1%). Infusion should be interrupted and medications for the treatment of anaphylaxis should be available for immediate use. High drug concentration and rate of infusion, as well as presence of polysorbate 80 and benzyl alcohol in the etoposide intravenous formulation, have been suggested as contributing factors to the development of hypersensitivity reactions. Etoposide intravenous formulations may contain polysorbate 80 and/or benzyl alcohol, while etoposide phosphate (the water soluble prodrug of etoposide) intravenous formulation does not contain either vehicle. Case reports have suggested that etoposide phosphate has been used successfully in patients with previous hypersensitivity reactions to etoposide (Collier 2008; Siderov 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Hypotension may occur due to rapid administration; infuse slowly over at least 30 to 60 minutes. If hypotension occurs, interrupt infusion and administer IV hydration and supportive care; decrease infusion upon reinitiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancies: Secondary acute leukemias have been reported with etoposide, either as monotherapy or in combination with other chemotherapy agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage should be adjusted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypoalbuminemia: Use with caution in patients with low serum albumin; may increase risk for toxicities.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; dosage should be adjusted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in elderly patients; may be more likely to develop severe myelosuppression and/or GI effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: The use of concentrations higher than recommended were associated with higher rates of anaphylactic-like reactions in children.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcohol: Injectable formulation contains alcohol (~33% v/v); may contribute to adverse reactions, especially with higher etoposide doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Must be diluted; do not give IV push, infuse over at least 30 to 60 minutes; hypotension is associated with rapid infusion. Etoposide is an irritant; tissue irritation and inflammation have occurred following extravasation. Do not administer IM or SubQ.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169328\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169250\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13292&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Atovaquone: May increase the serum concentration of Etoposide. Management: Consider separating the administration of atovaquone and etoposide by at least 1 to 2 days.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May decrease the metabolism of Etoposide. Management: Consider reducing the dose of etoposide by 50% if the patient is receiving, or has recently received, cyclosporine. Monitor for increased toxic effects of etoposide if cyclosporine is initiated, the dose is increased, or it has been recently discontinued.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Etoposide. Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide.  If these combinations cannot be avoided, monitor patients closely for diminished etoposide response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Etoposide may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169252\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2565787\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Fetal growth restriction and newborn myelosuppression have been observed following maternal use of regimens containing etoposide during pregnancy (NTP 2013; Peccatori 2013). The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided during in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation. Guidelines for the treatment of SCLC are not provided (Peccatori 2013). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In women of reproductive potential, product labeling for etoposide phosphate notes that it may cause amenorrhea, infertility, or premature menopause; effective contraception should be used during therapy and for &ge;6 months after the last dose. In males, azoospermia, oligospermia, or permanent loss of fertility may occur. In addition, spermatozoa and testicular tissue may be damaged. Males with female partners of reproductive potential should use condoms during therapy and for &ge;4 months after the last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1047332\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, hemoglobin, vital signs (blood pressure) during infusion, albumin, bilirubin, liver and renal function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169244\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Etoposide has been shown to delay transit of cells through the S phase and arrest cells in late S or early G<sub>2</sub> phase. The drug may inhibit mitochondrial transport at the NADH dehydrogenase level or inhibit uptake of nucleosides into HeLa cells. It is a topoisomerase II inhibitor and appears to cause DNA strand breaks. Etoposide does not inhibit microtubular assembly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169261\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Significant inter- and intrapatient variation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Average V<sub>d</sub>: Children: 10 L/m<sup>2</sup>; Adults: 7 to 17 L/m<sup>2</sup>; poor penetration across the blood-brain barrier; CSF concentrations &lt;5% of plasma concentrations </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 94% to 98% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic, via CYP3A4 and 3A5, to various metabolites; in addition, conversion of etoposide to the O-demethylated metabolites (catechol and quinine) via prostaglandin synthases or myeloperoxidase occurs, as well as glutathione and glucuronide conjugation via GSTT1/GSTP1 and UGT1A1 (Yang, 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~50% (range: 25% to 75%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: IV: Normal renal/hepatic function: Children: 6 to 8 hours: Adults: 4 to 11 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: IV: Urine (~55% as unchanged drug) in 24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: IV: Urine (56%; 45% as unchanged drug) within 120 hours; feces (44%) within 120 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10938424\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;\">Etoposide 10 mg/mL oral solution: Dilute etoposide for injection 1:1 with normal saline to a concentration of 10 mg/mL. This solution is stable in plastic oral syringes for 22 days at room temperature (McLeod 1992). Prior to oral administration, further mix with fruit juice (orange or apple <b>NOT</b> grapefruit juice) or lemonade to a concentration of &lt;0.4 mg/mL; once mixed with fruit juice, use within 3 hours (Lam 2011).</p>\n    <div class=\"reference\">Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-92.<span class=\"pubmed-id\">21275495</span></div>\r\n\n    <div class=\"reference\">McLeod HL and Relling MV, &ldquo;Stability of Etoposide Solution for Oral Use,&rdquo; <i>Am J Hosp Pharm</i>, 1992, 49(11):2784-5.<span class=\"pubmed-id\">1471649</span></div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323139\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Etoposide Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (20): $2,008.78</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Etoposide Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $149.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $11.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/25 mL (25 mL): $74.63</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Toposar Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 gm/50 mL (50 mL): $91.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (5 mL): $11.24</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/25 mL (25 mL): $45.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F169265\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actitop (LK);</li>\n      <li>Cavep (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Celltop (FR);</li>\n      <li>Citodox (AR);</li>\n      <li>Cryosid (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Ebeposide (SG);</li>\n      <li>Eposide (BD);</li>\n      <li>Eposin (CO, MY, TH, TW, ZW);</li>\n      <li>Epsidox (CL);</li>\n      <li>Etocris (PY);</li>\n      <li>Etoglob (LK);</li>\n      <li>Etonco (MX);</li>\n      <li>Etopa (LK);</li>\n      <li>Etopos (MX);</li>\n      <li>Etoposid (AE, CY, IL, JO, KW, QA);</li>\n      <li>Etoposide (AU, IL, NZ);</li>\n      <li>Etoposide Pierre Fabre (LU);</li>\n      <li>Etoposide Teva (HU);</li>\n      <li>Etoposido (PE);</li>\n      <li>Etopside (EG);</li>\n      <li>Etopul (ID, PH);</li>\n      <li>Etosid (IN, VE);</li>\n      <li>Etozyd (UA);</li>\n      <li>Fitozyd (UA);</li>\n      <li>Fytosid (ET, VN);</li>\n      <li>Lastet (AE, BG, CL, EG, HK, HU, IN, JO, JP, KR, LK, MY, PE, QA, SA, SG, TH, TW, VN);</li>\n      <li>Lastet-S (KR);</li>\n      <li>Posid (PH);</li>\n      <li>Posyd (ID);</li>\n      <li>Sintopozid (HK);</li>\n      <li>Topaxin (BD);</li>\n      <li>Topo (TH);</li>\n      <li>Tosuben (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Vepesid (AR, AT, BE, BR, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HN, IE, IT, JP, LB, MT, NL, NO, PH, PK, PL, PT, RO, RU, SE, SI, SK, TR, TW, UY, ZA);</li>\n      <li>VePesid (AU, HR, LU);</li>\n      <li>Vepeside (FR);</li>\n      <li>Vepsid (EG);</li>\n      <li>VP-Gen (EC, PY);</li>\n      <li>VP-TEC (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abu-Ghosh AM, Krailo MD, Goldman SC, et al, &quot;Ifosfamide, Carboplatin and Etoposide in Children With Poor-Risk Relapsed Wilms' Tumor: A Children's Cancer Group Report,&quot; <i>Ann Oncol</i>, 2002, 13(3):460-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11996479/pubmed\" target=\"_blank\" id=\"11996479\">11996479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. <i>J Clin Oncol</i>. 1991;9(7):1210-1214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/2045861/pubmed\" target=\"_blank\" id=\"2045861\">2045861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Archimbaud E, Thomas X, Leblond V, et al. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. <i>J Clin Oncol</i>. 1995;13(1):11-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/7799010/pubmed\" target=\"_blank\" id=\"7799010\">7799010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Archimbaud E, Leblond V, Michallet M, et al. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia. <i>Blood</i>. 1991;77(9):1894-1900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/2018832/pubmed\" target=\"_blank\" id=\"2018832\">2018832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azuno Y, Kaku K, Fujita N, Okubo M, Kaneko T, Matsumoto N. Mitoxantrone and etoposide in breast milk. <i>Am J Hematol</i>. 1995;48(2):131-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/7847330 /pubmed\" target=\"_blank\" id=\"7847330 \">7847330 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berg SL, Grisell DL, DeLaney TF, et al, &ldquo;Principles of Treatment of Pediatric Solid Tumors,&rdquo; <i>Pediatr Clin North Am</i>, 1991, 38(2):249-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/2006077/pubmed\" target=\"_blank\" id=\"2006077\">2006077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biagi E, Rovelli A, Balduzzi A, et al, &quot;TBI, Etoposide and Cyclophosphamide as a Promising Conditioning Regimen for BMT in Childhood ALL in Second Remission,&quot; <i>Bone Marrow Transplant</i>, 2000, 26(11):1260-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11149746/pubmed\" target=\"_blank\" id=\"11149746\">11149746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boos J, Kr&uuml;mpelmann S, Schulze-Westhoff P, et al, &ldquo;Steady-State Levels and Bone Marrow Toxicity of Etoposide in Children and Infants: Does Etoposide Require Age-Dependent Dose Calculation?&rdquo; <i>J Clin Oncol</i>, 1995, 13(12):2954-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/8523060/pubmed\" target=\"_blank\" id=\"8523060\">8523060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chantada G, Fandi&ntilde;o A, Casak S, Manzitti J, Raslawski E, Schvartzman E. Treatment of overt extraocular retinoblastoma. <i>Med Pediatr Oncol</i>. 2003;40(3):158-161.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12518344/pubmed\" target=\"_blank\" id=\"12518344\">12518344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12518344/pubmed\" target=\"_blank\" id=\"12518344\">12518344</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark PI and Slevin ML, &ldquo;The Clinical Pharmacology of Etoposide and Teniposide,&rdquo; <i>Clin Pharmacokinet</i>, 1987, 12(4):223-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/3297462 /pubmed\" target=\"_blank\" id=\"3297462 \">3297462 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Collier K, Schink C, Young AM, et al, &quot;Successful Treatment With Etoposide Phosphate in Patients With Previous Etoposide Hypersensitivity,&quot; <i>J Oncol Pharm Pract</i>, 2008, 14(1):51-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/18337441/pubmed\" target=\"_blank\" id=\"18337441\">18337441</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper TM, Franklin J, Gerbing RB, et al, &quot;AAML03P1, A Pilot Study of the Safety of Gemtuzumab Ozogamicin in Combination With Chemotherapy for Newly Diagnosed Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group,&quot;<i> Cancer</i>, 2012, 118(3):761-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21766293/pubmed\" target=\"_blank\" id=\"21766293\">21766293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daw NC, Gregornik D, Rodman J, et al, &quot;Renal Function After Ifosfamide, Carboplatin and Etoposide (ICE) Chemotherapy, Nephrectomy and Radiotherapy in Children With Wilms Tumour,&quot;<i> Eur J Cancer</i>, 2009, 45(1):99-106.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/18996004/pubmed\" target=\"_blank\" id=\"18996004\">18996004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 Study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25542311/pubmed\" target=\"_blank\" id=\"25542311\">25542311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donelli MG, Zucchetti M, Munzone E, D'Incalci M, Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. <i>Eur J Cancer</i>. 1998;34(1):33-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/9624235/pubmed\" target=\"_blank\" id=\"9624235\">9624235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreyer ZE, Dinndorf PA, Camitta B, et al. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2011;29(2):214-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21135279/pubmed\" target=\"_blank\" id=\"21135279\">21135279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). <i>Pediatr Blood Cancer</i>. 2015;62(3):419-426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25399948/pubmed\" target=\"_blank\" id=\"25399948\">25399948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duerst RE, Horan JT, Liesveld JL, et al, &quot;Allogeneic Bone Marrow Transplantation for Children With Acute Leukemia: Cytoreduction With Fractionated Total Body Irradiation, High-Dose Etoposide and Cyclophosphamide,&quot; <i>Bone Marrow Transplant</i>, 2000, 25(5):489-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/10713624/pubmed\" target=\"_blank\" id=\"10713624\">10713624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Duffner PK, Horowitz ME, Krischer JP, et al, &quot;Postoperative Chemotherapy and Delayed Radiation in Children Less Than Three Years of Age With Malignant Brain Tumors,&quot; <i>N Engl J Med</i>, 1993, 328(24):1725-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/8388548/pubmed\" target=\"_blank\" id=\"8388548\">8388548</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dunkel IJ, Gardner SL, Garvin JH Jr, Goldman S, Shi W, Finlay JL. High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma. <i>Neuro Oncol</i>. 2010;12(3):297-303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/20167818/pubmed\" target=\"_blank\" id=\"20167818\">20167818</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al; Pediatric Oncology Group of Ontario. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fangusaro J, Finlay J, Sposto R, et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. <i>Pediatr Blood Cancer</i>. 2008;50(2):312-31<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/17668858/pubmed\" target=\"_blank\" id=\"17668858\">17668858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleischhack G, Reif S, Hasan C, Jaehde U, Hettmer S, Bode U. Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumours. <i>Br J Cancer</i>. 2001;84(11):1453-1459.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11384092/pubmed\" target=\"_blank\" id=\"11384092\">11384092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &quot;Hepatotoxicity of Chemotherapy,&quot; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11384092/pubmed\" target=\"_blank\" id=\"11384092\">11384092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25311218/pubmed\" target=\"_blank\" id=\"25311218\">25311218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gamis AS, Alonzo TA, Meshinchi S, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children&rsquo;s Oncology Group trial AAML0531. <i>J Clin Oncol</i>. 2014;32(27):3021-3032<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25092781/pubmed\" target=\"_blank\" id=\"25092781\">25092781</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gibson BE, Webb DK, Howman AJ, et al, &quot;Results of a Randomized Trial in Children With Acute Myeloid Leukaemia: Medical Research Council AML12 Trial,&quot; <i>Br J Haematol</i>, 2011, 155(3):366-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21902686/pubmed\" target=\"_blank\" id=\"21902686\">21902686</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Bouffet E, Fisher PG, et al. Phase II trial assessing the ability of neoadjuvant chemotherapy with or without second-look surgery to eliminate measurable disease for nongerminomatous germ cell tumors: a Children's Oncology Group Study. <i>J Clin Oncol</i>. 2015;33(22):2464-2471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/26101244/pubmed\" target=\"_blank\" id=\"26101244\">26101244</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grier HE, Krailo MD, Tarbell NJ, et al, &quot;Addition of Ifosfamide and Etoposide to Standard Chemotherapy for Ewing's Sarcoma and Primitive Neuroectodermal Tumor of Bone,&quot; <i>N Engl J Med</i>, 2003, 348(8):694-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12594313/pubmed\" target=\"_blank\" id=\"12594313\">12594313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol</i>. 2012,30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hijiya N, Thomson B, Isakoff MS, et al. Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. <i>Blood</i>. 2011;118(23):6043-6049.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21967976/pubmed\" target=\"_blank\" id=\"21967976\">21967976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horning SJ, Negrin RS, Chao JC, et al, &quot;Fractionated Total-Body Irradiation, Etoposide, and Cyclophosphamide Plus Autografting in Hodgkin's Disease and Non-Hodgkin's Lymphoma,&quot;<i> J Clin Oncol</i>, 1994, 12(12):2552-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/7989928/pubmed\" target=\"_blank\" id=\"7989928\">7989928</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V. Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.<i> Ann Onco</i>. 2010;21(7):1395-1403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaneko M, Tsuchida Y, Mugishima H, et al, &quot;Intensified Chemotherapy Increases the Survival Rates in Patients With Stage 4 Neuroblastoma With MYCN Amplification,&quot; <i>J Pediatr Hematol Oncol</i>, 2002, 24(8):613-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12439032/pubmed\" target=\"_blank\" id=\"12439032\">12439032</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Hutchinson RJ, Sposto R, et al, &quot;Feasibility of Upfront Dose-Intensive Chemotherapy in Children With Advanced-Stage Hodgkin's Lymphoma: Preliminary Results From the Children's Cancer Group Study CCG-59704,&quot; <i>Ann Oncol</i>, 2002,13 Suppl 1:107-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12078889/pubmed\" target=\"_blank\" id=\"12078889\">12078889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, Sposto R, Hutchinson R, et al, &quot;BEACOPP Chemotherapy is a Highly Effective Regimen in Children and Adolescents With High-Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group,&quot; <i>Blood</i>, 2011, 117(9):2596-603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21079154/pubmed\" target=\"_blank\" id=\"21079154\">21079154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King PD, Perry MC. Hepatotoxicity of chemotherapy. <i>Oncologist</i>. 2001;6(2):162-176.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11306728/pubmed\" target=\"_blank\" id=\"11306728\">11306728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &quot;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&quot; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, Beatty K, Seto A, Einarson TR, Lishner M. The effects of impaired liver function on the elimination of antineoplastic agents. <i>Ann Pharmacother</i>. 1992;26(3):363-371.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/1554959/pubmed\" target=\"_blank\" id=\"1554959\">1554959</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kovnar EH, Kellie SJ, Horowitz ME, et al, &quot;Preirradiation Cisplatin and Etoposide in the Treatment of High-Risk Medulloblastoma and Other Malignant Embryonal Tumors of the Central Nervous System: A Phase II Study,&quot; <i>J Clin Oncol</i>, 1990, 8(2):330-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/2153766/pubmed\" target=\"_blank\" id=\"2153766\">2153766</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kung FH, Pratt CB, Vega RA, et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. <i>Cancer</i>. 1993;71(5):1898-1903.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/8448755/pubmed\" target=\"_blank\" id=\"8448755\">8448755</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Kramer K, LaQuaglia MP, et al, &quot;Reduction From Seven to Five Cycles of Intensive Induction Chemotherapy in Children With High-Risk Neuroblastoma,&quot; <i>J Clin Oncol</i>, 2004, 22(24):4888-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/15611504/pubmed\" target=\"_blank\" id=\"15611504\">15611504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. <i>J Clin Oncol</i>. 1995;13(11):2796-2804.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/7595741/pubmed\" target=\"_blank\" id=\"7595741\">7595741</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kushner BH, Modak S, Kramer K, Basu EM, Roberts SS, Cheung NK. Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literature. <i>Cancer</i>. 2013;119(3):665-671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/22951749/pubmed\" target=\"_blank\" id=\"22951749\">22951749</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam MS. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. <i>Pharmacotherapy</i>. 2011;31(2):164-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21275495/pubmed\" target=\"_blank\" id=\"21275495\">21275495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazarus HM, Creger RJ, and Diaz D, &ldquo;Simple Method for the Administration of High-Dose Etoposide During Autologous Bone Marrow Transplantation,&rdquo; <i>Cancer Treat Rep</i>, 1986, 70(6):819-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/3524832/pubmed\" target=\"_blank\" id=\"3524832\">3524832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee JW, Kang HJ, Kim S, et al. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients. <i>Biol Blood Marrow Transplant</i>. 2015;21(1):190-195<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25255163/pubmed\" target=\"_blank\" id=\"25255163\">25255163</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marina NM, Smeland S, Bielack ss, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. <i>Lancet Oncol</i>. 2016;17(10):1396-1408.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/27569442/pubmed\" target=\"_blank\" id=\"27569442\">27569442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matthay KK, Villablanca JG, Seeger RC, et al, &quot;Treatment of High-Risk Neuroblastoma With Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-Cis-Retinoic Acid. Children's Cancer Group,&quot; <i>N Engl J Med</i>, 1999, 341(16):1165-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/10519894/pubmed\" target=\"_blank\" id=\"10519894\">10519894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLeod HL, Relling MV. Stability of etoposide solution for oral use. <i>Am J Hosp Pharm.</i> 1992;49(11):2784-2785.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/1471649/pubmed\" target=\"_blank\" id=\"1471649\">1471649</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milano GM, Cozza R, Ilari I, et al. High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Ges&ugrave; Children's Hospital experience. <i>Cancer</i>. 2006;106(8):1838-1845.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/16532434/pubmed\" target=\"_blank\" id=\"16532434\">16532434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miser JS, Goldsby RE, Chen Z, et al. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group. <i>Pediatr Blood Cancer</i>. 2007;49(7):894-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/17584910/pubmed\" target=\"_blank\" id=\"17584910\">17584910</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Toxicology Program (NTP) Monograph on Developmental Effects and Pregnancy Outcomes Associated with Cancer Chemotherapy Use during Pregnancy, May 2013. Available at <a href=\"http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html\" target=\"_blank\">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Navid F, Santana VM, Billups CA, et al, &quot;Concomitant Administration of Vincristine, Doxorubicin, Cyclophosphamide, Ifosfamide, and Etoposide for High-Risk Sarcomas: The St. Jude Children's Research Hospital Experience,&quot; <i>Cancer</i>, 2006, 106(8):1846-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/16541446/pubmed\" target=\"_blank\" id=\"16541446\">16541446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishikawa A, Nakamura Y, Nobori U, et al, &ldquo;Acute Monocytic Leukemia in Children. Response to VP-16-213 as a Single Agent,&rdquo; <i>Cancer</i>, 1987, 60(9):2146-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/3326651 /pubmed\" target=\"_blank\" id=\"3326651 \">3326651 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Dwyer PJ, Leyland-Jones B, Alonso MT, et al, &ldquo;Etoposide (VP-16-213): Current Status of an Active Anticancer Drug,&rdquo; <i>N Engl J Med</i>, 1985, 312(11):692-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/2983208 /pubmed\" target=\"_blank\" id=\"2983208 \">2983208 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pajtler KW, Tippelt S, Siegler N, et al. Intraventricular etoposide safety and toxicity profile in children and young adults with refractory or recurrent malignant brain tumors. <i>J Neurooncol</i>. 2016;128(3):463-471.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/27147083/pubmed\" target=\"_blank\" id=\"27147083\">27147083</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park JR, Villablanca JG, London WB, et al, &quot;Outcome of High-Risk Stage 3 Neuroblastoma With Myeloablative Therapy and 13-Cis-Retinoic Acid: A Report From the Children's Oncology Group,&quot; <i>Pediatr Blood Cancer</i>, 2009, 52(1):44-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/18937318/pubmed\" target=\"_blank\" id=\"18937318\">18937318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker C, Waters R, Leighton C, &quot;Effect of Mitoxantrone on Outcome of Children With First Relapse of Acute Lymphoblastic Leukaemia (ALL R3): An Open-Label Randomised Trial,&quot; <i>Lancet</i>, 2010, 376(9757):2009-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/21131038/pubmed\" target=\"_blank\" id=\"21131038\">21131038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/23813932 /pubmed\" target=\"_blank\" id=\"23813932 \">23813932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perel Y, Auvrignon A, Leblanc T, et al, &quot;Impact of Addition of Maintenance Therapy to Intensive Induction and Consolidation Chemotherapy for Childhood Acute Myeloblastic Leukemia: Results of a Prospective Randomized Trial, LAME 89/91. Leuc&aacute;mie Aiq&uuml;e My&eacute;lo&iuml;de Enfant,&quot; <i>J Clin Oncol</i>, 2002, 20(12):2774-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/12065553/pubmed\" target=\"_blank\" id=\"12065553\">12065553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peyrl A, Chocholous M, Azizi AA, et al. Safety of Ommaya reservoirs in children with brain tumors: a 20-year experience with 5472 intraventricular drug administrations in 98 patients. <i>J Neurooncol</i>. 2014;120(1):139-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/25017328/pubmed\" target=\"_blank\" id=\"25017328\">25017328</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/19584400/pubmed\" target=\"_blank\" id=\"19584400\">19584400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siderov J, Prasad P, De Boer R, et al, &quot;Safe Administration of Etoposide Phosphate After Hypersensitivity Reaction to Intravenous Etoposide,&quot; <i>Br J Cancer</i>, 2002, 86(1):12-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/11857004/pubmed\" target=\"_blank\" id=\"11857004\">11857004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon T, L&auml;ngler A, Berthold F, et al, &quot;Topotecan and Etoposide in the Treatment of Relapsed High-Risk Neuroblastoma: Results of a Phase 2 Trial,&quot; <i>J Pediatr Hematol Oncol</i>, 2007, 29(2):101-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/17279006/pubmed\" target=\"_blank\" id=\"17279006\">17279006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simon T, L&auml;ngler A, Harnischmacher U, et al, &quot;Topotecan, Cyclophosphamide, and Etoposide (TCE) in the Treatment of High-Risk Neuroblastoma. Results of a Phase-II Trial,&quot; <i>J Cancer Res Clin Oncol</i>, 2007a, 133(9):653-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/17479288/pubmed\" target=\"_blank\" id=\"17479288\">17479288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Snyder DS, Chao NJ, Amylon MD, et al, &quot;Fractionated Total Body Irradiation and High-Dose Etoposide as a Preparatory Regimen for Bone Marrow Transplantation for 99 Patients With Acute Leukemia in First Complete Remission,&quot;<i> Blood</i>, 1993, 82(9):2920-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/8219241/pubmed\" target=\"_blank\" id=\"8219241\">8219241</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Superfin D, Iannucci AA, and Davies AM, &quot;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&quot; <i>Oncologist</i>, 2007, 12(9):1070-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/17914077/pubmed\" target=\"_blank\" id=\"17914077\">17914077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor RE, Bailey CC, Robinson K, et al, &quot;Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study,&quot; <i>J Clin Oncol</i>, 2003, 21(8):1581-91.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Winkle P, Angiolillo A, Krailo M, et al, &quot;Ifosfamide, Carboplatin, and Etoposide (ICE) Reinduction Chemotherapy in a Large Cohort of Children and Adolescents With Recurrent/Refractory Sarcoma: The Children's Cancer Group (CCG) Experience,&quot; <i>Pediatr Blood Cancer</i>, 2005, 44(4):338-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/15503297/pubmed\" target=\"_blank\" id=\"15503297\">15503297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang J, Bogni A, Schuetz EG, &ldquo;Etoposide Pathway,&rdquo; <i>Pharmacogenet Genomics</i>, 2009, 19(7):552-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/19512958/pubmed\" target=\"_blank\" id=\"19512958\">19512958</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zander AR, Berger C, Kr&ouml;ger N, et al, &quot;High Dose Chemotherapy With Busulfan, Cyclophosphamide, and Etoposide as Conditioning Regimen for Allogeneic Bone Marrow Transplantation for Patients With Acute Myeloid Leukemia in First Complete Remission,&quot; <i>Clin Cancer Res</i>, 1997, 3(12 Pt 2):2671-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/etoposide-pediatric-drug-information/abstract-text/10068272/pubmed\" target=\"_blank\" id=\"10068272\">10068272</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13292 Version 182.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708769\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F169278\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F14225985\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1047333\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1047325\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F169256\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F169241\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1047337\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132492\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F169272\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1047336\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F169342\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F169338\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F169262\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F169245\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F169328\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F169250\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F169252\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2565787\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1047332\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F169244\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F169261\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F10938424\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323139\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F169265\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13292|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">Etoposide: Drug information</a></li><li><a href=\"topic.htm?path=etoposide-patient-drug-information\" class=\"drug drug_patient\">Etoposide: Patient drug information</a></li></ul></div></div>","javascript":null}